Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to 98.56%.

  • Maravai Lifesciences Holdings' EBIT Margin rose 1413700.0% to 98.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 100.9%, marking a year-over-year decrease of 268100.0%. This contributed to the annual value of 90.91% for FY2024, which is 799500.0% down from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' EBIT Margin stood at 98.56%, which was up 1413700.0% from 139.84% recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBIT Margin peaked at 75.87% during Q3 2021, and registered a low of 239.93% during Q3 2024.
  • Over the past 5 years, Maravai Lifesciences Holdings' median EBIT Margin value was 9.64% (recorded in 2023), while the average stood at 11.16%.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' EBIT Margin crashed by -2168800bps in 2024 and then skyrocketed by 1413700bps in 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' EBIT Margin (Quarter) stood at 67.65% in 2021, then fell by -21bps to 53.37% in 2022, then crashed by -118bps to 9.64% in 2023, then crashed by -591bps to 66.66% in 2024, then plummeted by -48bps to 98.56% in 2025.
  • Its EBIT Margin was 98.56% in Q3 2025, compared to 139.84% in Q2 2025 and 104.93% in Q1 2025.